Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)

Condition:   Mammary Cancer Interventions:   Drug: Pertuzumab and trastuzumab FDC subcutaneous;   Drug: Paclitaxel;   Drug: TDM1;   Drug: Endocrine therapy;   Procedure: Omission surgery Sponsors:   David Garcia Cinca;   Fundacion Clinic per a la Recerca Biomédica Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials